Clinical Trials

109 enrolled

CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT04886531 2026-04-08

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT06109467 2026-02-09

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

36 enrolled

Gastrointestinal

Stomach Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

140 enrolled 32 charts

Breast Neoplasms

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast Neoplasms

NCT05933395 2026-01-20

GERTRUDE

135 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04965064 2025-12-15

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

22 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02977780 2025-11-10

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

460 enrolled

CNS

Glioblastoma

NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2 Not yet recruiting

30 enrolled

Carcinoma, Lobular

NCT07152782 2025-09-03

THUNDER

202 enrolled

Breast Cancer With Brain Metastasis

NCT03094052 2025-06-26

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

11 enrolled 12 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT05252988 2025-04-01

DIANER

177 enrolled

Breast Neoplasms

NCT06083662 2025-03-18

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Phase 2 Not yet recruiting

42 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

25 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

NCT05388149 2025-01-31

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

15 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT03812393 2023-12-18

FACT-2

Phase 2 Unknown

27 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04901299 2023-08-01

HER2-Signal

Phase 2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

NCT04781374 2023-07-11

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02673398 2023-06-18

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

25 enrolled 18 charts

HER2 Positive Breast Carcinoma

NCT04460430 2022-10-25

NEREA

Phase 2 Terminated

12 enrolled

Breast Neoplasms

NCT01670877 2022-04-15

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

56 enrolled 29 charts

Breast Neoplasms

NCT04856475 2022-03-02

NeraBrain

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Phase 2 Unknown

120 enrolled

CNS

Brain Neoplasms

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

1,150 enrolled